The United Nations Population Fund (UNFPA) and the Global Forum on MSM & HIV (MSMGF) have created this tool for implementing comprehensive sexual health services for men who have sex with men (MSM). Working together with UNDP, WHO, USAID, PEPFAR and over 100 experts from around the world, this publication targets public health officials and program managers, as well as NGOs and health workers implementing HIV and STI programs with MSM.
Implementing Comprehensive HIV and STI Programs with Men Who Have Sex With Men: Practical Guidance for Collaborative Interventions
Prevention Now: An Integration Agenda For Women, By Women
The Prevention Now report is the product of a meeting convened by CHANGE and AVAC in June 2015 in Nairobi. Advocates from across sub-Saharan Africa and the US leading advocacy efforts on sexual and reproductive health and rights, HIV prevention and treatment, gender based violence, sex worker rights, youth health and rights, maternal health and abortion access organizations came together to develop an advocacy agenda around integration.
Oral Pre-Exposure Prophylaxis – Putting a new choice in context
The World Health Organization (WHO) released updated guidance in late 2015 on oral pre-exposure prophylaxis (PrEP), containing tenofovir (TDF), as an additional HIV prevention choice. The new guidance is significantly broader than previously and creates real opportunities to move forward with implementing PrEP as part of comprehensive HIV programmes.
This publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.
HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.
Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).
A one-page summary document is also available.
HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape (1-pager)
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.
Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).
Px Wire July-September 2015, Vol. 8, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy.
In this issue, we describe the calls to expand ART access to all who need it, which have been amplified over the two months since the results of the START trial. We also document a growing demand for PrEP and the need for updated guidance from the WHO and targets from UNAIDS. And we look at the increasing role civil society is playing at developing PEPFAR Country Operating Plans (COPs) which guide targets, geography, interventions and budget levels on an annual basis.
In our centerspread, we look backwards and forward, at the conferences that took place in Vancouver and Durban in 1996 and 2000 and will again this year and the next.
This issue is also available as a webpage.
Px Wire April-June 2015, Vol. 8, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, you’ll find updates and how WHO is approaching broader guidance on oral PrEP and a closer look at passive immunization.
Our centerspread provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Proceedings from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants.
AVAC Report 2014/15: HIV Prevention on the Line
In AVAC Report 2014/15: HIV Prevention on the Line, we take on the current state of global targets for the AIDS response, looking beyond pithy slogans to explore what’s in place and what’s not in terms of targets, resources and action to begin to end the AIDS epidemic. We also provide concise updates and calls to action on key prevention interventions including AIDS vaccines, voluntary medical male circumcision, microbicides, PrEP, and hormonal contraception use and HIV risk.
Px Wire January-March 2015, Vol. 8, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue includes a highly selective list of ten issues, events and developments to hold attention and spark actions in 2015—and beyond. This issue is also available as a webpage.